| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 50242-0103-01 | 50242-0103 | polatuzumab vedotin | POLIVY | 30.0 mg/1.88mL | Immunotherapy | Drug Antibody Conjugate | CD79b | Intravenous | Sep 18, 2020 | In Use | |
| 00002-7716-01 | 00002-7716 | Necitumumab | Portrazza | 16.0 mg/mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Nov 24, 2015 | May 27, 2026 | No Longer Used |
| 61755-0054-01 | 61755-0054 | Linvoseltamab-gcpt | LYNOZYFIC | 5.0 mg/2.5mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Intravenous | Jul 2, 2025 | In Use | |
| 59572-0503-21 | 59572-0503 | Pomalidomide | Pomalyst | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 18, 2013 | In Use | |
| 43598-0517-21 | 43598-0517 | Pomalidomide | Pomalidomide | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Aug 31, 2026 | In Use | |
| 31722-0770-21 | 31722-0770 | Pomalidomide | Pomalidomide | 1.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 28, 2026 | In Use | |
| 57894-0502-20 | 57894-0502 | Daratumumab | Darzalex | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Nov 16, 2015 | Nov 30, 2024 | In Use |
| 50242-0260-86 | 50242-0260 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | May 3, 2021 | In Use | |
| 55513-0141-01 | 55513-0141 | trastuzumab-anns | Kanjinti | 150.0 mg/7.15mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Oct 28, 2019 | In Use | |
| 00480-4018-21 | 00480-4018 | Pomalidomide | Pomalidomide | 1.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 2, 2026 | In Use | |
| 00480-4022-21 | 00480-4022 | Pomalidomide | Pomalidomide | 2.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 2, 2026 | In Use | |
| 00007-3262-01 | 00007-3262 | Tositumomab, Iodine I-131 | Bexxar Therapeutic | Immunotherapy | Radioimmunotherapy | CD20 | Jul 15, 2009 | Feb 20, 2014 | No Longer Used | ||
| 00006-3083-01 | 00006-3083 | Pembrolizumab and berahyaluronidase alfa-pmph | KEYTRUDA QLEX | 2000.0 U/mL, 165.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Subcutaneous | Sep 19, 2025 | In Use | |
| 70377-0049-13 | 70377-0049 | Lenalidomide | Lenalidomide | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2025 | In Use | |
| 45802-0076-00 | 45802-0076 | Imiquimod | Imiquimod | 50.0 mg/1000mg | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Apr 20, 2010 | Aug 1, 2013 | No Longer Used |
| 00085-1388-01 | 00085-1388 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | Mar 29, 2011 | Jan 13, 2016 | No Longer Used | ||
| 00003-6120-01 | 00003-6120 | Nivolumab and hyaluronidase-nvhy | OPDIVO QVANTIG | 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Subcutaneous | Jan 2, 2025 | In Use | |
| 60505-4535-01 | 60505-4535 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | Mar 8, 2023 | In Use |
| 31722-0258-28 | 31722-0258 | LENALIDOMIDE | LENALIDOMIDE | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
| 43598-0515-21 | 43598-0515 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
| 73776-0001-12 | 73776-0001 | Lifileucel | AMTAGVI | 72000000000.0 1/500mL | Immunotherapy | Tumor Infiltrating Lymphocytes (TILs) | CD4+T, CD8+T | Intravenous | Feb 16, 2024 | In Use | |
| 82143-0001-01 | 82143-0001 | Bevacizumab | Avzivi | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jan 1, 2025 | In Use | |
| 60219-1716-02 | 60219-1716 | Lenalidomide | LENALIDOMIDE | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 12, 2025 | In Use | |
| 82293-0010-10 | 82293-0010 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jan 6, 2026 | In Use | |
| 76282-0701-48 | 76282-0701 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use |
Found 12611 results — Export these results
Home